Related Experiment Video

Updated: Jul 4, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

[Clinical efficiency of ivabradine in patients with cardiorespiratory pathology]

N M Kolomoets, V I Bakshiev, E G Zarubina

    Klinicheskaia Meditsina
    |July 1, 2008
    PubMed

    Insights

    Ivabradine effectively treats cardiorespiratory pathology (CRP) by reducing angina and improving exercise capacity. This If-inhibitor offers an alternative to beta-blockers without impacting respiratory function.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Cardiorespiratory pathology (CRP) presents significant challenges in patient management.
    • Current treatments may have limitations or side effects impacting quality of life.

    Purpose of the Study:

    • To evaluate the clinical efficiency of the If-inhibitor ivabradine in patients with CRP.
    • To assess the impact of ivabradine on angina symptoms, exercise tolerance, and cardiac function.

    Main Methods:

    • A study involving 40 patients diagnosed with cardiorespiratory pathology.
    • Administration of ivabradine at a dose of 5 mg twice daily.

    Main Results:

    • Significant reduction in weekly angina attacks and painless myocardial ischemia.
    • Decreased heart rate, improved 6-minute walking distance, and enhanced oxygen saturation.
    • Reduced pulmonary artery pressure and increased left ventricular ejection fraction.

    Conclusions:

    • Ivabradine (Coraxan, Servier) is an effective antianginal drug for CRP patients, improving quality of life.
    • Ivabradine does not negatively affect external respiration function.
    • Low-dose ivabradine can serve as an alternative to beta-blockers in CRP patients.

    More Related Videos

    Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

    Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

    Published on: December 11, 2017

    Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System10:17

    Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

    Published on: April 11, 2025

    Related Concept Videos

    Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

    Cardiopulmonary Resuscitation IV: Pharmacological Management

    Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

    Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
    Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

    Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

    Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
    Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
    Heart Failure Drugs: Inotropic Agents01:26

    Heart Failure Drugs: Inotropic Agents

    Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
    Cardiomyopathy II: Dilated Cardiomyopathy01:30

    Cardiomyopathy II: Dilated Cardiomyopathy

    Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...